A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants

January 5, 2026 updated by: OHB Neonatology Ltd.

A Phase 2b, Multicenter, Randomized, Open-label, Two-Arm Study to Evaluate the Clinical Efficacy and Safety of OHB-607 Compared to Standard Neonatal Care for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease of Prematurity

The purpose of this study is to determine if an investigational drug can prevent Bronchopulmonary Dysplasia, reducing the burden of chronic lung disease in extremely premature infants, as compared to extremely premature infants receiving standard neonatal care alone.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
338

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Australia
      • Parkville, Australia, 3052
        • Recruiting
        • Royal Women's Hospital
      • South Brisbane, Australia, Qld 4101
        • Recruiting
        • Mater Misericordiae Limited
    • New South Wales
      • Randwick, New South Wales, Australia, 2031
        • Recruiting
        • Royal Hospital for Women
  • Canada
      • Toronto, Canada, M5G 1X5
        • Withdrawn
        • Mount Sinai Hospital
    • Quebec
      • Montreal, Quebec, Canada
        • Recruiting
        • Sainte Justine Hospital
  • Finland
      • Oulu, Finland, 90220
        • Recruiting
        • Oulun yliopistollinen sairaala
  • France
      • Paris, France, 75015
        • Active, not recruiting
        • Groupe Hospitalier Necker Enfants Malades
    • Hauts-de-Seine
      • Clamart, Hauts-de-Seine, France, 92140
        • Active, not recruiting
        • Hôpital Antoine Béclère
  • Germany
      • Nuremberg, Germany, 90479
        • Recruiting
        • Klinikum Nürnberg
    • Baden-Wurttemberg
      • Freiburg im Breisgau, Baden-Wurttemberg, Germany, 79106
        • Withdrawn
        • Universitätsklinikum Freiburg
    • Saxony
      • Leipzig, Saxony, Germany, 04103
        • Recruiting
        • Universitätsklinikum Leipzig
  • Ireland
    • Wilton
      • Cork, Wilton, Ireland, T12YE02
        • Recruiting
        • Cork University Maternity Hospital
  • Italy
      • Florence, Italy, 50134
        • Recruiting
        • Azienda Ospedaliero-Universitaria Careggi SOD Neonatologia e Terapia Intensiva Neonatale
      • Genova, Italy, 16147
        • Recruiting
        • Istituto Giannina Gaslini-Istituto Pediatrico di Ricovero e
      • Treviso, Italy, 31100
        • Recruiting
        • Presidio Ospedaliero Di Treviso Ca' Foncello
    • Lazio
      • Rome, Lazio, Italy, 00168
        • Recruiting
        • Fondazione Policlinico Universitario A Gemelli
    • Lombardy
      • Milan, Lombardy, Italy, 20122
        • Recruiting
        • Fondazione IRCCS CA Granda Ospedale Maggiore Policlinico
    • Veneto
      • Padua, Veneto, Italy, 35128
        • Recruiting
        • Azienda Ospedaliera di Padova
  • Japan
      • Tokyo, Japan, 183-8561
        • Recruiting
        • Tokyo Metropolitan Children's Medical Center
      • Tokyo, Japan, 142-8666
        • Recruiting
        • Showa Medical University Hospital
    • Kagoshima-ken
      • Kagoshima, Kagoshima-ken, Japan, 890-0055
        • Active, not recruiting
        • Kagoshima City Hospital
    • Nagano
      • Azumino, Nagano, Japan, 399-8205
        • Recruiting
        • Nagano Children's Hospital
    • Okayama-ken
      • Kurashiki-shi, Okayama-ken, Japan, 710-0052
        • Recruiting
        • Kurashiki Central Hospital
    • Saitama
      • Kawagoe-shi, Saitama, Japan, 350-8550
        • Recruiting
        • Saitama Medical Center
    • Ôsaka
      • Izumi, Ôsaka, Japan, 594-1101
        • Recruiting
        • Osaka Women's and Children's Hospital
  • Netherlands
      • Utrecht, Netherlands, 3584 EA
        • Recruiting
        • Wilhelmina Children Hospital-University Medical Center Utrecht
    • Limburg
      • Maastricht, Limburg, Netherlands, 6229 HX
        • Recruiting
        • Maastricht University Medical Center
    • North Holland
      • Amsterdam-Zuidoost, North Holland, Netherlands, 1105 AZ
        • Recruiting
        • Academisch Medisch Centrum Amsterdam
  • Portugal
      • Almada, Portugal, 2801-951
        • Recruiting
        • Hospital Garcia de Orta
      • Lisbon, Portugal, 1069-089
        • Recruiting
        • Maternidade Alfredo da Costa
      • Lisbon, Portugal, 1649-035
        • Recruiting
        • Centro Hospitalar Lisboa
      • Porto, Portugal, 4050-651
        • Recruiting
        • Centro Materno Infantil do Norte - Centro Hospital Universitario do Porto, E.P.E.
  • Spain
      • Alicante, Spain, 03010
        • Recruiting
        • Hospital General Universitario Dr. Balmis
  • Sweden
      • Lund, Sweden, SE-22185
        • Completed
        • Skanes universitetssjukhus
      • Stockholm, Sweden, 171 76
        • Withdrawn
        • Karolinska Solna
  • United Kingdom
      • Cambridge, United Kingdom, CB2 0QQ
        • Recruiting
        • University of Cambridge
      • Coventry, United Kingdom, CV2 2DX
        • Recruiting
        • University Hospital Coventry
      • Liverpool, United Kingdom, L69 3BX
        • Recruiting
        • Liverpool Women's Hospital - PPDS
      • London, United Kingdom, NW1 2BU
        • Withdrawn
        • University College London
      • London, United Kingdom, SW3 6JJ
        • Recruiting
        • Chelsea and Westminster NHS Trust
      • Manchester, United Kingdom, M13 9WL
        • Recruiting
        • St. Mary's Hospital
    • Norfolk
      • Norwich, Norfolk, United Kingdom, NR4 7UY
        • Recruiting
        • Norfolk and Norwich University Hospital
    • Surrey
      • Chertsey, Surrey, United Kingdom, KT16 0PZ
        • Completed
        • Ashford and St. Peter's Hospitals NHS Trust - St. Peter's Hospital
  • United States
    • Arkansas
      • Little Rock, Arkansas, United States, 72202-3500
        • Recruiting
        • Arkansas Children's Hospital
      • Little Rock, Arkansas, United States, 72202-3500
        • Recruiting
        • University of Arkansas for Medical Sciences
    • California
      • California City, California, United States, 92868
        • Recruiting
        • Children's Hospital of Orange County
      • Los Angeles, California, United States, 90033-1804
        • Active, not recruiting
        • LAC USC Medical Center
    • Florida
      • Miami, Florida, United States, 33136-1005
        • Recruiting
        • Jackson Memorial Hospital
      • Tampa, Florida, United States, 33606-3571
        • Recruiting
        • Tampa General Hospital
    • Illinois
      • Chicago, Illinois, United States, 60612
        • Recruiting
        • University of Illinois at Chicago
    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Recruiting
        • Riley Hospital for Children
      • South Bend, Indiana, United States, 46601-1078
        • Recruiting
        • Memorial Hospital of South Bend
    • Kentucky
      • Louisville, Kentucky, United States, 40202
        • Recruiting
        • Norton Children's Hospital
    • Louisiana
      • New Orleans, Louisiana, United States, 70115
        • Recruiting
        • Ochsner Baptist Medical Center
    • Massachusetts
      • Boston, Massachusetts, United States, 02115
        • Withdrawn
        • Boston Children's Hospital
      • Boston, Massachusetts, United States, 02111-1553
        • Recruiting
        • Tufts Medical Center
    • Minnesota
      • Saint Paul, Minnesota, United States, 55102
        • Recruiting
        • Children's Minnesota - Children's Hospital and Clinics - St. Paul
      • Saint Paul, Minnesota, United States, 55102
        • Recruiting
        • Children's Minnesota - Children's Hospital and Clinics
    • Mississippi
      • Jackson, Mississippi, United States, 39216-4500
        • Recruiting
        • University of Mississippi Medical Center
    • New York
      • Rochester, New York, United States, 14627
        • Recruiting
        • University of Rochester
      • Valhalla, New York, United States, 10595
        • Recruiting
        • Maria Fareri Children's Hospital
    • Ohio
      • Columbus, Ohio, United States, 43205
        • Not yet recruiting
        • Nationwide Children's Hospital
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73104
        • Recruiting
        • University of Oklahoma Health Sciences Center
    • South Carolina
      • Charleston, South Carolina, United States, 29425-8908
        • Recruiting
        • Medical University of South Carolina Children Hospital
    • Virginia
      • Charlottesville, Virginia, United States, 22903
        • Recruiting
        • UVA Children's Hospital
      • Richmond, Virginia, United States, 23298-5075
        • Recruiting
        • Virginia Commonwealth University - Children's Hospital of Richmond at VCU

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

1 second to 1 day (Child)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Written informed consents and/or assents must be signed and dated by the participant's parent(s) prior to any study related procedures. The informed consent and any assents for underage parents must be approved by the IRB/IEC (in accordance with local regulations).
  2. Written informed consents and/or assents must be signed and dated by the participant's birth mother prior to providing study-related information related to birth mother medical history, pregnancy and the birth of the participant. The informed consent and any assents for underage birth mothers must be approved by the IRB/IEC (in accordance with local regulations).
  3. Subjects must be between 23 weeks +0 days and 27 weeks +6 days GA, inclusive.

Exclusion Criteria:

  1. Detectable major (or severe) congenital malformation identified before randomization.
  2. Known or suspected chromosomal abnormality, genetic disorder, or syndrome, identified before randomization, according to the investigator's opinion.
  3. Hypoglycemia at Baseline (blood glucose less than (<) 45 milligrams per deciliter [mg/dL] or 2.5 milli moles per liter [mmol/L]) which persists in spite of glucose supplementation, to exclude severe congenital abnormalities of glucose metabolism.
  4. Clinically significant neurological disease identified before randomization according to cranial ultrasound (hemorrhages confined to the germinal matrix are allowed) and investigator's opinion.
  5. Any other condition or therapy that, in the investigator's opinion, may pose a risk to the participant or interfere with the participant's potential compliance with this protocol or interfere with interpretation of results.
  6. Current or planned participation in a clinical study of another investigational study treatment, device, or procedure (participation in non-interventional studies is permitted on a case-by-case basis).
  7. The participant or participant's parent(s) is/are unable to comply with the protocol or is unlikely to be available for long-term follow-up as determined by the investigator.
  8. Birth mother with active COVID-19 infection at birth or a history of severe COVID-19 infection (requiring intensive care hospitalization) during pregnancy.
  9. Birth mother with known HIV or hepatitis (B, C, or E) infection.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: OHB-607
Participants will receive continuous IV infusion of OHB-607 through from birth up to PMA 29 weeks +6 days.
Drug: OHB-607
Participants will receive intravenous infusion of OHB-607 from birth up to PMA 29 weeks + 6 days.
Other Names:
  • Mecasermin Rinfabate
No Intervention: Standard Neonatal Care
Standard neonatal care alone will be provided.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Reduction in the incidence of severe Bronchopulmonary Dysplasia (BPD) at 36 weeks (±3 days) Postmenstrual Age (PMA), or death at or before 36 weeks PMA, whichever comes first as compared to the SNC group.
Time Frame: Baseline through 36 weeks postmenstrual age (PMA)
Severe BPD is defined by the modified NICHD severity grading
Baseline through 36 weeks postmenstrual age (PMA)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Incidence and severity of BPD
Time Frame: Baseline through 36 weeks postmenstrual age (PMA)
BPD severity is defined by the modified NICHD severity grading
Baseline through 36 weeks postmenstrual age (PMA)
Incidence of Retinopathy of Prematurity (ROP)
Time Frame: Baseline through 40 weeks PMA
ROP is classified according to the International Classification
Baseline through 40 weeks PMA
Reducing the burden of Chronic Lung Disease, as indicated by a reduction in time to final weaning off of Respiratory Technology Support (RTS) through 12 months Corrected Age (CA), as compared to the SNC group.
Time Frame: Baseline through 12 months CA
The final weaning off of RTS is defined as the 7th consecutive day that the subject is off RTS.
Baseline through 12 months CA
Reduction in the incidence of severe BPD at 36 weeks (±3 days) PMA, or death at or before 36 weeks PMA, whichever comes first as compared to the SNC group.
Time Frame: Time Frame: Baseline through 36 weeks postmenstrual age (PMA)
Severe BPD is defined based on the classification according to Jensen et al., 2019
Time Frame: Baseline through 36 weeks postmenstrual age (PMA)
Occurrence of severe (Grade 3 and 4) intraventricular hemorrhage (IVH) before 40 weeks PMA, as assessed by cranial ultrasound as compared to the SNC group
Time Frame: Baseline through 40 weeks postmenstrual age (PMA)
Severe IVH as classified according to the Volpe criteria
Baseline through 40 weeks postmenstrual age (PMA)
To assess the effect of OHB-607 on occurrence of severe retinopathy of prematurity (ROP) (Stage 3 and above) up to 40 weeks PMA as compared to the SNC group
Time Frame: Baseline through 40 weeks postmenstrual age (PMA)
Baseline through 40 weeks postmenstrual age (PMA)
To assess the effect of OHB-607 on chronic respiratory outcomes as measured by the Chronic Lung Disease Prematurity Severity Score (CLDPSS) as compared to the SNC group at 12 months CA.
Time Frame: Baseline until 12 months CA using CLDPSS
Baseline until 12 months CA using CLDPSS
The effect of OHB-607 on neurodevelopment is measured by the Cognitive, Language and Motor Scales of the Bayley Scales of Infant and Toddler Development (BSID) III as compared to the SNC group at 24 months CA.
Time Frame: Time Frame: Determined by the separate BSID III scales at 24 months CA
Time Frame: Determined by the separate BSID III scales at 24 months CA
Chronic respiratory morbidity outcomes at 24 months CA
Time Frame: 24 months CA
24 months CA
Jensen BPD grade at 36 weeks PMA (± 3 days), as classified according to Jensen et al., 2019. Incidence of all severity grades of BPD as assessed by Jensen et al., 2019
Time Frame: 36 weeks weeks postmenstrual age (PMA) (± 3 days)
36 weeks weeks postmenstrual age (PMA) (± 3 days)
Incidence and severity of IVH
Time Frame: Baseline through 36 weeks postmenstrual age (PMA)
Incidence of all grades of IVH as assessed by centrally read CUS and classified according to the Volpe criteria
Baseline through 36 weeks postmenstrual age (PMA)
Neurodevelopment outcomes
Time Frame: From 6 months CA through 24 months CA
Neurodevelopmental impairment, Physical and cognitive development will be measured by ASQ®-3 administered at 12 and 24 months CA.
From 6 months CA through 24 months CA
Mortality from randomization through to 24 months CA
Time Frame: From birth through 24 months CA
Mortality rates from randomization to initial hospital discharge and from initial discharge through 24 months CA.
From birth through 24 months CA
Exposure-response relationship between measured IGF-1 and Bronchopulmonary Dysplasia (BPD)
Time Frame: Baseline through 36 weeks PMA
Blood samples will be collected to measure IGF-1 and these measured values will be associated with the incidence and severity grade of BPD
Baseline through 36 weeks PMA
Exposure-response relationship between measured IGF-1 and intraventricular hemorrhage (IVH)
Time Frame: Baseline through 40 weeks PMA
Blood samples will be collected to measure IGF-1 and these measured values will be associated with the incidence and severity grade of IVH
Baseline through 40 weeks PMA
Exposure-response relationship between measured IGF-1 and necrotizing enterocolitis (NEC)
Time Frame: Baseline through 40 weeks PMA
Blood samples will be collected to measure IGF-1 and these measured values will be associated with the incidence and severity grade of NEC
Baseline through 40 weeks PMA
Exposure-response relationship between measured IGF-1 and Retinopathy of Prematurity (ROP)
Time Frame: Baseline through 40 weeks PMA
Blood samples will be collected to measure IGF-1 and these measured values will be associated with the incidence and severity grade of ROP
Baseline through 40 weeks PMA
To assess the safety profile of OHB-607 as compared to the SNC group.
Time Frame: Baseline through 24 months CA
Incidence, severity, and causality assessment of Adverse Events (AEs) and Serious Adverse Events (SAEs), including Fatal AEs as per the neonatal adverse event severity scale.
Baseline through 24 months CA

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
OHB Neonatology Ltd.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 9, 2019

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 23, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 21, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 15, 2017

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 15, 2017

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 17, 2017

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 7, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 5, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • OHB-607-202
  • 2018-001393-16 (EudraCT Number)
  • jRCT2071200076 (Registry Identifier: jRCT)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

De-identified individual participant data from this particular study will not be shared in order to minimize the risk that individual patients could be re-identified, given that there are limited numbers of study participants at each study site per year.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intraventricular Hemorrhage

Clinical Trials on OHB-607

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings